

# Jesus G Berdeja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9270070/publications.pdf>

Version: 2024-02-01

41  
papers

3,339  
citations

567281

15  
h-index

345221

36  
g-index

41  
all docs

41  
docs citations

41  
times ranked

3353  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 1726-1737.	27.0	1,130
2	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	27.0	1,129
3	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1503-1512.	10.7	233
4	Ciltacabtagene Autoleucel, an Anti-CD19 B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	1.6	160
5	CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 127, 3360-3368.	1.4	89
6	Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, 670-676.	3.5	82
7	Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 129-138.	0.4	68
8	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. <i>Blood</i> , 2014, 124, 3553-3560.	1.4	56
9	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	1.4	56
10	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	7.2	45
11	Lorvotuzumab mertansine: antibody-drug-conjugate for CD56 <sup>+</sup> multiple myeloma. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 163.	3.0	41
12	Twice-weekly ixazomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244.	2.5	30
13	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
14	Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 561-567.	2.0	22
15	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , 2021, 100, 2325-2337.	1.8	21
16	Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 345-356.	2.3	21
17	Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 3928-3928.	1.4	13
18	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 2384-2393.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. British Journal of Haematology, 2018, 180, 365-373.	2.5	10
20	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. American Journal of Hematology, 2019, 94, 794-802.	4.1	10
21	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 752-765.	0.4	10
22	A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 911-911.	1.4	10
23	New approaches to blood and marrow transplantation for patients with low-grade lymphomas. Current Opinion in Oncology, 2001, 13, 335-341.	2.4	7
24	Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. British Journal of Haematology, 2017, 177, 254-262.	2.5	6
25	A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose expansion cohort. American Journal of Hematology, 2021, 96, 428-435.	4.1	6
26	A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM). Blood, 2019, 134, 603-603.	1.4	6
27	A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2021, 96, 226-233.	4.1	5
28	An Open-Label, Phase Ib Study of Duvelisib (IPI-145) in Combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with Lymphoma or Chronic Lymphocytic Leukemia. Blood, 2014, 124, 4422-4422.	1.4	5
29	A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts. Blood, 2015, 126, 1825-1825.	1.4	5
30	A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion. Blood, 2016, 128, 4530-4530.	1.4	5
31	Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2013, 31, 8502-8502.	1.6	5
32	Blood and Bone Marrow Transplantation for Patients with Hodgkin's and Non-Hodgkin's Lymphoma. , 2006, 131, 251-281.		3
33	Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 2461-2461.	1.4	3
34	Practical aspects of building a new immunotherapy program: the future of cell therapy. Hematology American Society of Hematology Education Program, 2020, 2020, 579-584.	2.5	2
35	Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.. Blood, 2010, 116, 2799-2799.	1.4	2
36	A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).. Journal of Clinical Oncology, 2012, 30, TPS8115-TPS8115.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.. Journal of Clinical Oncology, 2018, 36, 8022-8022.	1.6	2
38	A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma. Blood, 2015, 126, 1492-1492.	1.4	1
39	An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S240-S241.	0.4	0
40	A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 3336-3336.	1.4	0
41	Clinical Utility of High-Throughput and Complimentary Genomic Tumor Profiling in Hematologic Malignancies. Blood, 2015, 126, 1388-1388.	1.4	0